ClinicalTrials.gg
CompletedNCT07848919CACTUSUpdated Sep 30, 2026

Combined tDCS and Cognitive Neurorehabilitation in Post-Stroke Depression

An interventional study of Active transcranial direct current stimulation and Sham transcranial direct current stimulation in Ischemic Stroke and Depressive Symptoms, sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida). Completed at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Apr 2024, registered Sep 2026).
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 137 studies in Ischemic Stroke with a site in Spain — 37 open to participants now, 46 under way, 7 of them phase 3. Ischemic Stroke · Spain.

Enrollment
89th of 97
33 · median 240
Started
2024
with 10 others
No phase
48 of 137
15 open now
Registered
135th of 137
by date

Among the 137 studies in Ischemic Stroke with a site in Spain, this one is the 89th largest by enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2024, is one of 48 with no phase, and was the 135th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

37 of the 137 studies in Ischemic Stroke with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Ischemic Stroke with a site in Spain, or all of them as a file.
02

Study summary

This study evaluates a multimodal intervention pathway for affective and cognitive symptoms after ischemic stroke. Patients undergo an initial screening of depressive symptoms, cognitive function, and quality of life. Participants meeting the criteria for intervention are randomized to one of four groups: active transcranial direct current stimulation (tDCS), sham tDCS, online cognitive neurorehabilitation, or a combined intervention using active tDCS and online cognitive neurorehabilitation. Clinical outcomes include depressive symptoms, cognitive performance, and quality of life assessed longitudinally during follow-up.

Read the detailed description

Patients admitted after an acute ischaemic stroke who meet the eligibility criteria and provide written informed consent undergo an initial screening assessment including depressive symptoms, cognitive function, and perceived quality of life. Participants who meet the predefined criteria for intervention enter the randomized treatment pathway.

Participants are randomized to one of four intervention groups: active tDCS, sham tDCS, online cognitive neurorehabilitation using Guttmann NeuroPersonalTrainer (GNPT), or a multimodal intervention combining active tDCS with GNPT. Active tDCS is delivered over the dorsolateral prefrontal cortex using an anode over the left DLPFC and a cathode over the right DLPFC, at an intensity of 2 mA for 30 minutes over 14 sessions. Participants assigned to GNPT complete 32 cognitive training sessions. In the multimodal group, active tDCS is combined with GNPT during the intervention period, together with additional home-based GNPT sessions.

Participants are followed longitudinally with repeated assessments of depressive symptoms, cognitive performance, and quality of life.

03

Conditions studied

  • Ischemic Stroke
  • Depressive Symptoms

Keywords

  • Post-stroke depression
  • Transcranial direct current stimulation
  • tDCS
  • Cognitive neurorehabilitation
  • GNPT
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Acute ischemic stroke confirmed by neuroimaging
  • Modified Rankin Scale (mRS) score ≤3 at discharge
  • NIH Stroke Scale (NIHSS) score ≤8 at discharge
  • Time from symptom onset to inclusion \<15 days
  • Time from ischemic stroke symptom onset to first neurological care \<48 hours

Exclusion criteria

Exclusion Criteria:

  • (TIA)
  • Language barrier preventing adequate understanding Catalan or Spanish
  • Severe pre-existing psychiatric disorder
  • Active diagnosed depression at the time of stroke
  • Pre-existing cognitive impairment
  • Severe aphasia, defined as a score ≥2 on item 9 and/or 10 of the NIHSS
  • History of alcoholism or substance abuse
  • \<12 months
  • History of seizures.
  • Unexplained episodes of loss of consciousness potentially related to epilepsy or other cerebral disorders.
  • Uncontrolled or unstable neuropsychiatric disorder.
  • Implanted medical devices in the brain.
  • Cardiac pacemaker.
  • Electrically, mechanically, or magnetically activated implants.
  • Cardiac, neural, or drug-delivery implants.
  • Vascular clips.
  • Severe brain lesions.
  • Skin lesions at the stimulation site
  • Dermatological conditions affecting the stimulation site, including dermatitis, psoriasis, or eczema.
  • Frequent or severe headaches.
  • Severe life-threatening medical conditions, including congestive heart failure, , or active .
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Active tDCS

    Participants receive 14 sessions of active transcranial direct current stimulation (tDCS). Stimulation is delivered at 2 mA for 30 minutes, with the anode positioned over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right DLPFC.

    Device: Active transcranial direct current stimulation

  • Sham comparator
    Sham tDCS

    Participants receive 14 sessions using the same electrode montage as the active tDCS group, but with sham stimulation delivered according to the study protocol

    Device: Sham transcranial direct current stimulation

  • Experimental
    Cognitive Neurorehabilitation

    Participants complete 32 online cognitive neurorehabilitation sessions of 30 minutes using Guttmann NeuroPersonalTrainer (GNPT).

    Behavioral: Cognitive neurorehabilitation using Guttmann NeuroPersonalTrainer

  • Experimental
    Multimodal Intervention

    Participants receive 14 sessions of active tDCS combined with cognitive neurorehabilitation using GNPT. The remaining 18 GNPT sessions are completed at home, for a total of 32 cognitive training sessions.

    Device: Active transcranial direct current stimulation · Behavioral: Cognitive neurorehabilitation using Guttmann NeuroPersonalTrainer

Interventions

  • DeviceActive transcranial direct current stimulation

    Active tDCS is delivered at 2 mA for 30 minutes over 14 sessions, with the anode positioned over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right DLPFC.

  • DeviceSham transcranial direct current stimulation

    Sham tDCS is delivered over 14 sessions using the same electrode montage as active tDCS, without therapeutic current stimulation.

  • BehavioralCognitive neurorehabilitation using Guttmann NeuroPersonalTrainer

    Participants complete 32 cognitive neurorehabilitation sessions of approximately 30 minutes each using Guttmann NeuroPersonalTrainer (GNPT). In the multimodal group, 14 GNPT sessions are performed concurrently with active tDCS and the remaining 18 sessions are completed at home.

06

What researchers measure

Primary outcomes

  1. Change in depressive symptoms measured with the 17-item Hamilton Depression Rating Scale (HDRS-17)

    Depressive symptoms are assessed using the 17-item Hamilton Depression Rating Scale (HDRS-17) at the pre-intervention assessment (T1), 3 months post-randomization (T2), and 6 months post-randomization (T3). Total scores range from 0 to 52, with higher scores indicating greater severity of depressive symptoms. In this study, a score ≥7 was considered indicative of affective impairment.

    Time frame: From initial screening through the 6-month follow-up period

Secondary outcomes

  1. Change in cognitive composite z-score

    Cognitive performance is assessed at the pre-intervention assessment (T1), 3 months post-randomization (T2), and 6 months post-randomization (T3). Raw neuropsychological test scores are converted into scaled scores using standardized population-based norms and subsequently transformed into z-scores. Domain-specific cognitive scores are calculated by averaging the z-scores of tests assigned to each cognitive domain. The global cognitive composite is calculated as the average z-score across all individual tests included in the neuropsychological battery. The composite z-score has no fixed minimum or maximum value; a score of 0 represents the normative mean and one z-score unit represents one standard deviation. Higher scores indicate better cognitive performance.

    Time frame: From randomization through the 6-month follow-up

  2. Change in perceived quality of life measured with the ECVI-38

    Perceived quality of life is assessed using the Stroke-Specific Quality of Life Scale (ECVI-38) at the pre-intervention assessment (T1), 3 months post-randomization (T2), and 6 months post-randomization (T3). The ECVI-38 is a 38-item stroke-specific measure. Each item is scored from 1 to 5, yielding a total score ranging from 38 to 190. Higher scores indicate poorer health-related quality of life.

    Time frame: From randomization through the 6-month follow-up

07

Study locations

1 site
  • Hospital Universitari Arnau de Vilanova
    Lleida, Lleida 25198, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Apr 2026, 24 months.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 24 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 30, 2026
StartActual
Apr 9, 2024
Primary completionActual
Apr 17, 2026
CompletionActual
Apr 17, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848919
Lead sponsor
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Apr 9, 2024
Primary completion
Apr 17, 2026
Completion
Apr 17, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion